Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25567947 | 0.94 | SIGMAR1 (0.37) | KDM1ASIGMAR1SLC6A4SLC6A3LMNA | |
| SCHEMBL22296937 | 0.89 | KDM1A (0.42) | KDM1ASIGMAR1SLC6A4SLC6A3TSHR | |
| SCHEMBL21421592 | 0.88 | SMN1; SMN2 (0.37) | KDM1ASIGMAR1SLC6A4SLC6A3LMNA | |
| SCHEMBL21421584 | 0.86 | SMN1; SMN2 (0.36) | KDM1ASIGMAR1SLC6A4SLC6A3LMNA | |
| SCHEMBL25133312 | 0.86 | KDM1A (0.35) | KDM1ASIGMAR1SLC6A4SLC6A3LMNA | |
| SCHEMBL26693373 | 0.85 | HRH3 (0.34) | — | |
| SCHEMBL24866025 | 0.83 | PIK3CD (0.42) | KDM1ASLC6A4SLC6A3 | |
| SCHEMBL10192139 | 0.83 | KDM1A (0.39) | KDM1ASIGMAR1 | |
| SCHEMBL6057217 | 0.82 | ALOX15 (0.38) | SIGMAR1 | |
| SCHEMBL20438382 | 0.82 | ALOX15 (0.38) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | KDM1A 2268/4885SIGMAR1 4371/4885SLC6A4 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.